Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM123 divergent transcript (TMEM123-DT) is a non-coding RNA gene annotated in genomic databases as an antisense or divergent transcript relative to the protein-coding gene TMEM123. This transcript does not encode a protein and, to date, lacks evidence as a biologically characterized or therapeutic target. All available mechanistic and disease association data pertains to the TMEM123 protein (also known as Porimin/KCT-3), a plasma membrane glycoprotein involved in immune cell migration and tumor immune surveillance, not to TMEM123-DT[1][2]. The protein-coding gene TMEM123 is sometimes confused with its divergent transcript TMEM123-DT, but all major literature and functional studies to date pertain only to TMEM123, not TMEM123-DT[1][2]. The term "TMEM123-DT" refers to a non-coding RNA, not a conventional therapeutic target (such as a receptor, enzyme, or transporter). TMEM123-DT is not a receptor, enzyme, or other conventional target and is likely included in error when searching for protein/gene therapeutic targets. All functional relevance is for TMEM123, not TMEM123-DT[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TMEM123 divergent transcript (TMEM123-DT).